Our comprehensive analysis aimed to elucidate the expression levels of GPSM1, GPSM2, GPSM3, and PCP2 across healthy controls and CRC patients, as well as to discern the gene expression patterns across different stages of CRC. This evidence concerns the gene GPSM3 and colorectal carcinoma.